Back to Search Start Over

Aldeyra suggests potential FDA rejection imminent for dry eye med after 'substantive review issues'.

Authors :
Bayer, Max
Source :
FierceBiotech; 10/17/2023, pN.PAG-N.PAG, 1p
Publication Year :
2023

Abstract

Aldyera's shares fell more than 60% after the biotech indicated the FDA could soon reject its dry eye disease med due to a lack of convincing data. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
DRY eye syndromes

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
173052512

Tools

Authors Abstract Subjects Details